Barclays
CATX icon

Barclays’s Perspective Therapeutics CATX Stock Holding History

Barclays’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.2K Buy
22,047
+6,998
+47% +$26.4K ﹤0.01% 4172
2026
Q1 		$62.8K Sell
15,049
-77,742
-84% -$328K ﹤0.01% 4227
2025
Q4 		$255K Buy
92,791
+8,936
+11% +$25.5K ﹤0.01% 4197
2025
Q3 		$288K Sell
83,855
-19,426
-19% -$70.8K ﹤0.01% 4130
2025
Q2 		$355K Buy
103,281
+45,388
+78% +$120K ﹤0.01% 3949
2025
Q1 		$123K Sell
57,893
-36,986
-39% -$111K ﹤0.01% 4316
2024
Q4 		$303K Sell
94,879
-19,196
-17% -$157K ﹤0.01% 4116
2024
Q3 		$1.52M Buy
114,075
+97,493
+588% +$1.3M ﹤0.01% 3072
2024
Q2 		$165K Buy
16,582
+9,681
+140% +$140K ﹤0.01% 3675
2024
Q1 		$82.1K Buy
+6,901
New +$58.8K ﹤0.01% 4502
2021
Q2 		– Sell
-174
Closed -$2K – 4882
2021
Q1 		$2K Buy
+174
New +$2.63K ﹤0.01% 4552
2018
Q2 		– Hold
0
– – – 6986
2018
Q1 		– Hold
0
– – – 7070

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Barclays's CATX Position: Q2 2026 in Review

Barclays increased its Perspective Therapeutics (CATX) stake by 47% in Q2 2026, buying an estimated $26.4K and bringing the position to 22,047 shares worth $75.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4172.

Barclays first reported a position in CATX in Q1 2021 and has held it in 11 quarters since. The position peaked at $1.52M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Barclays held 22,047 shares of Perspective Therapeutics worth $75.2K as of Q2 2026.
  • Barclays bought 6,998 Perspective Therapeutics shares in Q2 2026, an estimated $26.4K.
  • Perspective Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4172 holding.
  • Barclays first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Barclays's Perspective Therapeutics position peaked at $1.52M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.